Low-dose recombinant human interleukin-2
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Low-dose recombinant human interleukin-2, covering 2018-03-15 to 2018-03-15. Get the full timeline:
Most recent: Clinical Trial Update: A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome [Phase 2]